学术周报 · IF≥10 或专科旗舰刊
胆胰外科领域文献阅读汇编
2026年第46周 (2026-11-13) | PubMed (NLM) · DeepSeek 中英双语
数据来源: PubMed E-utilities · 影响因子筛选: IF≥10 或专科旗舰刊 · 完整摘要不截断
数据来源: PubMed E-utilities · 影响因子筛选: IF≥10 或专科旗舰刊 · 完整摘要不截断
★本周 Top 10 高影响力文献
Ŧ期刊分布统计
| 期刊 | 篇数 | IF |
|---|---|---|
| Cancer letters | 4 | IF 11.8 |
| Annals of surgery | 2 | IF 7.4 |
| Cancer cell | 2 | IF 56.1 |
| Science advances | 1 | IF 13.9 |
| Pharmacological research | 1 | IF 12.2 |
| EBioMedicine | 1 | IF 11.2 |
| Science translational medicine | 1 | IF 15.6 |
| Cancer discovery | 1 | IF 29.5 |
| Gut | 1 | IF 24.6 |
| Nature immunology | 1 | IF 26.5 |
1胰腺癌 (9篇)
基础研究 (9篇)
Pancreatic ductal adenocarcinoma (PDAC) remains difficult to treat, highlighting the need for strategies that selectively deliver cytotoxic agents to tumor cells. Trophoblast cell-surface antigen 2 (TROP2) has been proposed as a candidate therapeutic target in PDAC, but non-antibody-based delivery formats remain underexplored. Using protein-SELEX, we identified T17, a high-affinity aptamer that specifically binds to TROP2, and conjugated it to monomethyl auristatin E through an MC-Val-Cit-PAB linker to generate the aptamer-drug conjugate T17-M. Preclinical evaluation in cellular and animal models showed that T17-M retained TROP2-dependent binding, underwent clathrin-mediated internalization and lysosomal processing, and suppressed tumor growth in cell-line-derived and patient-derived xenografts. T17-M also reduced liver metastasis and induced calreticulin exposure, ATP release, and HMGB1 secretion, consistent with immunogenic cell death. In immunocompetent models, T17-M promoted dendritic-cell activation and CD8+ T cell infiltration, while its combination with PD-1 blockade further enhanced tumor control and prolonged survival. These findings provide preclinical proof-of-concept for T17-M as an alternative TROP2-targeted drug-delivery strategy for PDAC.
中文摘要:胰腺导管腺癌治疗困难,亟需能将细胞毒性药物选择性递送至肿瘤细胞的策略。滋养层细胞表面抗原2被提出作为胰腺导管腺癌的潜在治疗靶点,但基于非抗体载体的递送形式研究尚不充分。通过蛋白质SELEX技术,我们鉴定出一种高亲和力且特异性结合TROP2的适配体T17,并通过MC-Val-Cit-PAB连接子将其与单甲基澳瑞他汀E偶联,生成适配体药物偶联物T17-M。在细胞和动物模型中的临床前评估显示,T17-M保留了依赖TROP2的结合能力,经历网格蛋白介导的内吞作用和溶酶体加工,并在细胞系来源及患者来源异种移植模型中抑制肿瘤生长。T17-M还减少肝转移并诱导钙网蛋白暴露、ATP释放和HMGB1分泌,符合免疫原性细胞死亡特征。在免疫健全模型中,T17-M促进树突状细胞活化和CD8+ T细胞浸润,其与PD-1阻断联合使用进一步增强了肿瘤控制并延长生存期。这些发现为T17-M作为胰腺导管腺癌的替代TROP2靶向药物递送策略提供了临床前概念验证。
Perineural invasion (PNI) is a prominent feature of pancreatic cancer (PDAC) and is closely associated with tumor progression and poor prognosis. However, its spatial cellular architecture and underlying mechanisms remain incompletely understood. Here, we applied high-resolution spatial transcriptomics to construct a comprehensive atlas of the PNI microenvironment across distinct anatomical regions of intra and extra-pancreas. We observed that the Basal-like tumor subtype exhibited a higher propensity for PNI compared with the Classical subtype, a finding further supported by multiplex imaging on whole-mount histopathology. Comparative spatial analysis revealed distinct immune and stromal organization between tumor subtypes, with enrichment of M2-like macrophage potentially promoting epithelial cell migration in the vicinity of Basal-like tumors. In addition, we identified myofibroblast subset may promote Schwann cell activation and PNI-associated nerve injury was further accompanied by a shift toward inflammatory fibroblast polarization and features of CD8+ T cell exhaustion within the local microenvironment. Finally, spatial profiling indicated functional heterogeneity among tumor-associated Schwann cells, which may contribute to the tumor progression. Collectively, this study provides a spatially resolved view of the cellular and molecular landscape of PNI in PDAC and offers insights into Basal-specific neurotropic behavior and microenvironmental reorganization.
中文摘要:神经周围侵犯是胰腺导管腺癌的一个显著特征,与肿瘤进展和不良预后密切相关。然而,其空间细胞结构和潜在机制尚不完全清楚。本研究应用高分辨率空间转录组学技术,构建了胰腺内和胰腺外不同解剖区域神经周围侵犯微环境的综合图谱。我们观察到,与经典亚型相比,基底样肿瘤亚型表现出更高的神经周围侵犯倾向,这一发现在全切片组织病理学的多重成像中得到了进一步支持。比较空间分析揭示了不同肿瘤亚型之间免疫和基质组织的差异,其中M2样巨噬细胞的富集可能促进基底样肿瘤附近上皮细胞的迁移。此外,我们鉴定出肌成纤维细胞亚群可能促进施万细胞激活,神经周围侵犯相关的神经损伤还伴随着向炎症性成纤维细胞极化的转变以及局部微环境中CD8+ T细胞耗竭特征的出现。最后,空间谱系分析表明肿瘤相关施万细胞存在功能异质性,这可能有助于肿瘤进展。综上所述,本研究提供了胰腺导管腺癌神经周围侵犯细胞和分子景观的空间分辨率视图,并为基底特异性趋神经行为及微环境重组提供了见解。
Computed tomography (CT) stages pancreatic ductal adenocarcinoma (PDAC) but does not read out the treatment-guiding tumour biology, requiring biopsy. Whether an imaging-biology relationship discovered in preclinical MRI holds independently in human CT is unknown. One pipeline was applied to two PDAC cohorts: longitudinal 9.4 T multi-parametric MRI (169 sessions; 1002 image series, 471 quantitative maps) with terminal histopathology in male C57BL/6 mice bearing orthotopic KPC-derived tumours treated with gemcitabine, a dendritic-cell vaccine, both, or neither, and abdominal CT with matched proteogenomics from CPTAC-PDA. Radiomics and frozen foundation-model embeddings were modelled under grouped cross-validation against five pre-specified paired endpoints, with no cross-species transfer of features, weights, or labels. Applied independently, the pipeline recovered four matched molecular endpoints in both species (CD8 infiltration, stromal collagen, CD8:CD68 immune balance, cytolytic activity), with areas under the receiver-operating-characteristic curve (AUROCs) of 0.938-0.960 in mice and 0.780-0.856 in humans. Survival concordance indices were 0.729 and 0.689. After adjustment for age, stage, and grade, the human imaging score remained independently prognostic (hazard ratio 1.87 per SD, 95% CI 1.32 to 2.66; p < 0.001 [Wald test]; combined concordance index 0.726 versus 0.611 for clinical covariates). Findings held in portal-venous-restricted analysis; frozen embeddings outperformed end-to-end fine-tuning in both arms. One pipeline recovered matched PDAC biology in mouse MRI and human CT, supporting preclinical imaging to nominate non-invasive CT biomarker candidates for biopsy-sparing PDAC trial stratification, pending prospective external validation. National Cancer Institute; Society of Interventional Radiology Foundation; University of California Irvine Anticancer Challenge Pilot grant.
中文摘要:计算机断层扫描(CT)用于分期胰腺导管腺癌(PDAC),但无法读取指导治疗肿瘤生物学特征,因此需要活检。在临床前MRI中发现的影像学生物学关系是否在人类CT中独立成立尚不清楚。本研究将同一流程应用于两个PDAC队列:纵向9.4T多参数MRI(169次会话;1002个图像序列,471个定量图谱)结合终末组织病理学,对象为携带原位KPC衍生肿瘤并接受吉西他滨、树突状细胞疫苗、两者联合或无治疗的雄性C57BL/6小鼠;以及具有来自CPTAC-PDA匹配蛋白质组学的腹部CT。在分组交叉验证下,对五个预先指定的配对终点进行影像组学和冻结基础模型嵌入建模,未进行跨物种的特征、权重或标签转移。独立应用该流程后,在两个物种中均恢复了四个匹配的分子终点(CD8浸润、间质胶原、CD8:CD68免疫平衡、细胞毒性活性),小鼠的受试者工作特征曲线下面积(AUROC)为0.938-0.960,人类为0.780-0.856。生存一致性指数分别为0.729和0.689。在调整年龄、分期和分级后,人类影像评分仍具有独立的预后价值(每标准差风险比1.87,95%置信区间1.32至2.66;P < 0.001 [Wald检验];综合一致性指数0.726,而临床协变量为0.611)。在门静脉限制性分析中结果保持一致;冻结嵌入在两臂中均优于端到端微调。该流程在小鼠MRI和人类CT中恢复了匹配的PDAC生物学特征,支持利用临床前影像提名非侵入性CT生物标志物候选者,用于避免活检的PDAC试验分层,但需前瞻性外部验证。
Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal malignancy for which neoadjuvant chemotherapy with albumin-bound paclitaxel combined with gemcitabine (AG) is a standard first-line approach for borderline resectable and locally advanced disease. However, secondary resistance to this regimen is common, and its underlying mechanisms remain poorly defined. In this study, we investigated how neoadjuvant AG therapy shapes the tumor stroma in PDAC. Single-cell transcriptomics of patient tumors revealed that AG treatment induces a phenotypic switch of cancer-associated fibroblasts (CAFs) from myofibroblastic (myCAF) to inflammatory (iCAF) states and identified a previously unrecognized TMEM100+CAF subset enriched in nonresponders. Mechanistic studies showed that albumin-bound paclitaxel activates IL-2-STAT5 signaling to drive TMEM100 expression and that TMEM100+CAFs promote chemoresistance through paracrine secretion of amphiregulin (AREG) and activation of tumor EGFR signaling. Genetic ablation of TMEM100+CAFs in mouse models reversed CAF switching and enhanced the antitumor efficacy of AG therapy. These findings map chemotherapy-induced CAF plasticity, reveal a TMEM100-AREG axis of resistance, and highlight TMEM100+CAFs as a promising target to sensitize PDAC to neoadjuvant treatment.
中文摘要:胰腺导管腺癌是一种致死率极高的恶性肿瘤,对于交界可切除和局部晚期疾病,白蛋白结合型紫杉醇联合吉西他滨是标准的一线新辅助化疗方案。然而,对该方案的继发性耐药很常见,其潜在机制尚不明确。本研究探讨了新辅助AG治疗如何塑造胰腺导管腺癌的肿瘤间质。患者肿瘤的单细胞转录组学分析显示,AG治疗诱导癌症相关成纤维细胞从肌成纤维细胞状态向炎症状态发生表型转换,并鉴定出一个在非响应者中富集的先前未被认识的TMEM100+CAF亚群。机制研究表明,白蛋白结合型紫杉醇激活IL-2-STAT5信号通路以驱动TMEM100表达,而TMEM100+CAF通过旁分泌分泌双调蛋白并激活肿瘤EGFR信号通路促进化疗耐药。在小鼠模型中基因敲除TMEM100+CAF逆转了成纤维细胞转换并增强了AG治疗的抗肿瘤疗效。这些发现描绘了化疗诱导的成纤维细胞可塑性,揭示了耐药的TMEM100-双调蛋白轴,并突显了TMEM100+CAF作为增敏胰腺导管腺癌新辅助治疗的潜在靶点。
Fibrosis and tumor innervation are two features of the tumor microenvironment (TME) that contribute directly to the lethality of pancreatic ductal adenocarcinoma (PDAC), but their potential interactions have not been explored. Moreover, although it is known that activated Schwann cells (SCs) stimulate cancer cell invasion, it remains unclear how SCs are activated. We determined how SCs are activated in the pancreatic fibrotic microenvironment. The correlation between physical features of the microenvironment and SC activation was assessed in human patient samples and in mice by SC c-Jun phosphorylation monitoring, atomic force microscopy and multiphoton live imaging. Several in vitro models in which forces were applied to SCs expressing a reporter for c-Jun phosphorylation and RNA-Seq analysis were used to decipher the cellular and molecular mechanisms of SC activation. Nerves surrounded by stiff stroma present higher SC activation. Intravital imaging shows a matrix dependent SC activation. Mechanical forces on SCs induce c-Jun phosphorylation in SCs in a non-canonical manner that involves a nuclear sensing machinery with the proinflammatory enzyme Phospholipase A2. Fibrosis enhances the protumorigenic impact of innervation by activating SCs via a mechanism in which nuclear compression triggers non-canonical activation of the AP-1 transcription factor complex. Pancreatic fibrosis alone, without cancer cells, is sufficient to activate SCs, suggesting this mechanism may be common across non-malignant pancreatic diseases. Notably, SCs are more sensitive to mechanical activation than PDAC cells. These findings reveal TME interactions that may guide future microenvironment-targeted PDAC therapies.
中文摘要:纤维化和肿瘤神经支配是胰腺导管腺癌微环境的两个特征,直接导致其致死性,但两者的潜在相互作用尚未被探索。尽管已知活化的施万细胞刺激癌细胞侵袭,但其活化机制尚不清楚。本研究确定了施万细胞在胰腺纤维化微环境中的活化方式。通过监测施万细胞c-Jun磷酸化、原子力显微镜和多光子活体成像,在人样本和小鼠模型中评估了微环境物理特征与施万细胞活化的相关性。利用施加机械力的体外模型及表达c-Jun磷酸化报告基因的施万细胞进行RNA测序分析,以解析施万细胞活化的细胞和分子机制。结果显示,被僵硬基质包围的神经具有更高的施万细胞活化水平。体内成像显示施万细胞活化依赖于基质。施万细胞受到的机械力通过一种非经典方式诱导c-Jun磷酸化,该过程涉及含有促炎酶磷脂酶A2的核感知机制。纤维化通过核压缩触发AP-1转录因子复合物的非经典激活来增强神经支配的促肿瘤影响。仅胰腺纤维化而无癌细胞足以活化施万细胞,提示该机制可能在非恶性胰腺疾病中普遍存在。值得注意的是,施万细胞对机械活化的敏感性高于胰腺导管腺癌细胞。这些发现揭示了可能指导未来靶向微环境的胰腺导管腺癌治疗策略的微环境相互作用。
Tissue stiffening is a predominant malignant physical alteration in cancer progression, yet its effect on specific immune subsets within the tumor microenvironment is not well defined. Here we show that elevated tissue stiffness subverts tumor-infiltrating type 1 helper T (TH1) cells to drive immunosuppression in pancreatic cancer. Mechanistically, stiffness triggers integrin-mediated mechanotransduction to activate YAP, which translocates to the nucleus and cooperates with RUNX1 to transcriptionally upregulate a set of dysfunction-associated genes. These reprogrammed TH1 cells acquire a distinct dysfunction-associated secretory phenotype, which in turn drives M2-like polarization of macrophages and amplifies local immunosuppression. Notably, inhibiting YAP expression or disrupting YAP-RUNX1 interaction reverses the dysfunctional state of TH1 cells and restores antitumor immunity. These findings delineate a mechano-immunological mechanism by which tumor stiffness subverts TH1 cell functions, indicating a possible therapeutic avenue to alleviate immunosuppression and potentiate immunotherapy efficacy in stiff tumors.
中文摘要:组织硬化是癌症进展中主要的恶性物理改变,但其在肿瘤微环境中对特定免疫亚群的影响尚不明确。本研究显示,升高的组织硬度会颠覆浸润性1型辅助T(TH1)细胞的功能,从而驱动胰腺癌中的免疫抑制。机制上,硬度触发整合素介导的机械转导以激活YAP,后者易位至细胞核并与RUNX1协同转录上调一系列功能障碍相关基因。这些重编程的TH1细胞获得独特的功能障碍相关分泌表型,进而驱动巨噬细胞向M2样极化并放大局部免疫抑制。值得注意的是,抑制YAP表达或破坏YAP-RUNX1相互作用可逆转TH1细胞的功能障碍状态并恢复抗肿瘤免疫。这些发现描绘了一种机械免疫学机制,即肿瘤硬度如何颠覆TH1细胞功能,表明在硬化肿瘤中减轻免疫抑制并增强免疫治疗疗效存在潜在的治疗途径。
Existing treatment options for colorectal and pancreatic cancers harboring mutant p53 (p53mut) are largely ineffective and lack selectivity. Our novel therapeutic strategy for p53mut cancers with a thymidine analogue (TAS102) and a PARP inhibitor (PARPi) showed promising efficacy in a clinical trial, although the mechanisms remain not fully understood. Here, we investigated the molecular mechanisms underlying therapeutic efficacy of our approach and explored new combinations to further enhance the response. To define the contribution of each drug into the therapeutic response, we conducted an unbiased transcriptomic analysis in p53-proficient and p53mut cancer models. The biological effects were investigated in comprehensive analyses of cell proliferation, cell death, and DNA damage. The drug interactions were explored in cytotoxicity assays and efficacy was tested in patient-derived colorectal and pancreatic cancer models. We found that TAS102-PARPi treatment induces DNA breaks and long G2-arrest in p53mut cells, whereas normal cells rapidly repair their DNA and re-enter the cell cycle. Transcriptomic analysis showed that TAS102 is the major driver of the response, whereas PARPi improves selectivity of the TAS102 effects. The treatment does not block replication in p53mut cells but induces post-replicative DNA repair and represses mitosis. Delayed blockade of G2-checkpoint results in massive cell death in p53mut cells selectively. Priming TAS102-PARPi treatment in combination with delayed G2-checkpoint blockade was highly effective against cancer models and was well-tolerated in mice. Broadly, a novel two-step therapeutic strategy showed high efficacy and selectivity for p53mut cancers and low toxicity to normal tissues, demonstrating potential for clinical translation.
中文摘要:携带突变型p53(p53mut)的结直肠癌和胰腺癌现有治疗选择大多无效且缺乏选择性。我们针对p53mut癌症的新型联合治疗策略(使用胸苷类似物TAS102与PARP抑制剂PARPi)在临床试验中显示出令人鼓舞的疗效,但其机制尚未完全阐明。本研究旨在探讨该疗法疗效背后的分子机制,并探索新的组合以进一步增强反应。为了明确每种药物在治疗反应中的贡献,我们在p53野生型和p53mut癌症模型中进行了无偏倚的转录组学分析。通过综合分析细胞增殖、细胞死亡和DNA损伤来研究生物学效应。在细胞毒性试验中探讨了药物相互作用,并在患者来源的结直肠癌和胰腺癌模型中测试了疗效。我们发现TAS102联合PARPi治疗诱导p53mut细胞发生DNA断裂和长期G2期阻滞,而正常细胞则快速修复DNA并重新进入细胞周期。转录组学分析显示,TAS102是反应的主要驱动因素,而PARPi提高了TAS102效应的选择性。该治疗并未阻断p53mut细胞的复制,而是诱导复制后DNA修复并抑制有丝分裂。延迟的G2检查点阻滞导致p53mut细胞发生大规模选择性死亡。在癌症模型中,以TAS102联合PARPi预处理结合延迟G2检查点阻滞的策略具有高效性且在小鼠中耐受性良好。总体而言,这种新颖的两步治疗策略对p53mut癌症显示出高疗效和高选择性,并对正常组织毒性较低,展示了临床转化的潜力。
KRASG12D is a predominant driver in pancreatic cancer, yet the basis of intrinsic resistance to KRASG12D-targeted therapy remains poorly defined. Integrated genomics, transcriptomics, and proteomics profiling across 242 patient-derived organoids (PDOs) and matched tumor tissues reveals a KRASG12D-mutant subset intrinsically resistant to KRASG12D-targeted therapeutics, characterized by marked downregulation of innate immune signaling pathways. Functional validation demonstrates that suppressing interferon signaling in sensitive models induces resistance, whereas activation of interferon signaling, particularly interferon beta (IFN-β), increases sensitivity in resistant models. Combining IFN-β with KRAS inhibitors (MRTX1133, HRS-4642, and RMC-6236) exhibits synergistic antitumor effects in intrinsically resistant pancreatic cancer. Mechanistically, sustained MYC activity is associated with attenuated sensitivity to KRAS inhibition and correlates with repressed interferon signaling, suggesting a potential role in promoting intrinsic resistance. These findings identify interferon signaling as a candidate determinant of KRAS-targeted therapy response and support interferon-based combinations as a potential strategy for intrinsically resistant pancreatic cancer.
中文摘要:KRASG12D是胰腺癌的主要驱动基因,但其对KRASG12D靶向治疗产生内在耐药性的机制尚不明确。通过对242例患者来源类器官及其配对的肿瘤组织进行整合基因组学、转录组学和蛋白质组学分析,发现存在一个对KRASG12D靶向药物具有内在耐药性的KRASG12D突变亚群,其特征是先天免疫信号通路的显著下调。功能验证表明,在敏感模型中抑制干扰素信号传导可诱导耐药性,而在耐药模型中激活干扰素信号传导(特别是干扰素β)则能增加敏感性。将IFN-β与KRAS抑制剂(MRTX1133、HRS-4642和RMC-6236)联合使用,在具有内在耐药性的胰腺癌中表现出协同抗肿瘤作用。机制上,持续的MYC活性与对KRAS抑制的敏感性降低相关,并与干扰素信号传导的受抑相关,提示其在促进内在耐药性方面可能发挥作用。这些发现将干扰素信号确定为KRAS靶向治疗反应的一个潜在决定因素,并支持以干扰素为基础的联合疗法作为治疗内在耐药性胰腺癌的潜在策略。
Cancer-induced cachexia is a multifactorial syndrome characterized by systemic inflammation and progressive skeletal muscle and fat wasting. More than 80% pancreatic cancer patients exhibit a cachectic phenotype, which significantly contributes to the overall mortality of cancer patients. Till now, there is no FDA-approved therapy for cancer-associated cachexia that has been developed. In the present study, we have demonstrated the anti-cachectic potential of an anti-malarial compound, atovaquone. We observed that atovaquone inhibits cancer cell-conditioned media-induced myotube atrophy in a dose-dependent manner. Atovaquone treatments lead to reduced cachectic markers expression in conditioned media-treated myotubes. Further, we observed that atovaquone treatment results in reduced reactive oxygen species levels in conditioned media-treated myotubes. Mechanistically, we observed that atovaquone treatment of myotubes enhances the glycolytic capacity of conditioned-media-treated myotubes by upregulating Glut4 expression. Furthermore, we established that increased Glut4 expression is primarily driven by atovaquone-induced AMPK activation. By utilizing a syngeneic orthotopic implantation model of pancreatic cancer, we have observed that atovaquone can inhibit cachectic phenotype in tumor-bearing mice, without impacting the overall tumour growth. Overall, we have demonstrated that atovaquone exhibits anti-cachectic properties in both in vitro and in vivo model systems of pancreatic cancer-associated cachexia by modulating glycolytic capacity.
中文摘要:癌症诱导的恶病质是一种以全身性炎症和进行性骨骼肌及脂肪消耗为特征的多因素综合征。超过百分之八十的胰腺癌患者表现出恶病质表型,这显著增加了癌症患者的总体死亡率。迄今为止,尚未开发出获得美国食品药品监督管理局批准的治疗癌症相关恶病质的疗法。在本研究中,我们证明了抗疟药物阿托伐醌具有抗恶病质潜力。我们观察到阿托伐醌以剂量依赖性方式抑制癌细胞条件培养基诱导的肌管萎缩。阿托伐醌处理导致条件培养基处理的肌管中恶病质标志物表达减少。此外,我们观察到阿托伐醌处理降低了条件培养基处理的肌管中的活性氧水平。在机制上,我们发现阿托伐醌处理通过上调Glut4表达增强条件培养基处理的肌管的糖酵解能力。进一步的研究证实,Glut4表达的升高主要由阿托伐醌诱导的AMPK激活驱动。利用胰腺癌的同系原位植入模型,我们观察到阿托伐醌可以在不影响肿瘤总体生长的情况下抑制荷瘤小鼠的恶病质表型。总体而言,我们证明了阿托伐醌通过调节糖酵解能力在胰腺癌相关恶病质的体外和体内模型系统中表现出抗恶病质特性。
2胆管癌 (2篇)
基础研究 (2篇)
Dysregulation of cell cycle control contributes to the progression and therapeutic resistance of intrahepatic cholangiocarcinoma (ICC), yet the therapeutic potential of targeting this pathway remains incompletely understood. Here, we show that the cyclin-dependent kinase 4/6 (CDK4/6) inhibitor Dalpiciclib suppresses ICC progression, although its efficacy varies across patient-derived models. Mechanistically, Dalpiciclib inhibits CDK4-mediated phosphorylation of β-catenin at Ser675, thereby attenuating epithelial-mesenchymal transition (EMT) and metastatic phenotypes. We further identify miR-221-3p as a key post-transcriptional regulator of CDK4 signaling that modulates both ICC progression and sensitivity to dalpiciclib. Elevated miR-221-3p promotes CDKN1B downregulation, thereby relieving its inhibitory effect on CDK4, enhancing β-catenin phosphorylation, and facilitating metastatic progression. Notably, circulating miR-221-3p levels closely mirrored intratumoral miR-221-3p expression and were associated with Dalpiciclib sensitivity in corresponding patient-derived xenograft (PDX) models, suggesting its potential as a non-invasive biomarker for assessing treatment response. Collectively, these findings identify a miR-221-3p/CDKN1B/CDK4/β-catenin axis that links cell cycle regulation ICC progression and CDK4 inhibitor response, providing a mechanistic rationale for preclinical evaluation of Dalpiciclib treatment in ICC.
中文摘要:细胞周期控制失调导致肝内胆管癌(ICC)进展和治疗耐药,但靶向该通路的治疗潜力尚不完全清楚。本研究显示,CDK4/6抑制剂Dalpiciclib可抑制ICC进展,但其疗效在不同患者来源模型中存在差异。机制上,Dalpiciclib抑制CDK4介导的β-catenin在Ser675位点的磷酸化,从而减弱上皮间质转化(EMT)和转移表型。我们进一步发现miR-221-3p是调控CDK4信号的关键转录后调节因子,可调节ICC进展及对Dalpiciclib的敏感性。高水平的miR-221-3p促进CDKN1B下调,从而解除其对CDK4的抑制作用,增强β-catenin磷酸化并促进转移进展。值得注意的是,循环miR-221-3p水平与肿瘤内miR-221-3p表达高度一致,并与相应患者来源异种移植(PDX)模型中Dalpiciclib的敏感性相关,提示其作为评估治疗反应的无创生物标志物的潜力。综上所述,这些发现确定了一条miR-221-3p/CDKN1B/CDK4/β-catenin轴,该轴将细胞周期调节、ICC进展与CDK4抑制剂反应联系起来,为ICC中Dalpiciclib治疗的临床前评估提供了机制依据。
Adenosquamous carcinoma (ASC) in intrahepatic cholangiocarcinoma (iCCA) has long been considered rare (~1-2%), yet its occurrence portends lethal disease progression. Here, we identify latent squamous plasticity, a transcriptionally primed yet histology-silent state that is quantifiable by a squamous transition potential (STP) index. Approximately 20-30% of iCCA patients can be classified as STP-high and experience ASC-like dismal outcomes. Mechanistically, FOSL1 acts as a plasticity trigger, driving a temporally ordered squamous program by reshaping the chromatin landscape. Additionally, it cooperates with p63 in an enhancer-dependent manner to dysregulate PTGS2/COX-2 expression. The resulting intratumoral PGE2 accumulation drives neutrophil-mediated FOXP3-negative type 1 regulatory T-cell (Tr1) polarization and predisposes STP-high tumors to immunotherapy resistance. Through a drug-repurposing screen, we identify celecoxib as a dual-function agent that counteracts latent squamous plasticity while fostering an immune-permissive state, providing a clinically actionable strategy for squamous-biased iCCA now being evaluated in a phase Ib/II trial (NCT07632235).
中文摘要:肝内胆管癌(iCCA)中的腺鳞癌(ASC)长期被认为罕见(约1-2%),但其出现预示致命的疾病进展。本研究鉴定出一种潜在鳞状可塑性,这是一种转录预激活但组织学沉默的状态,可通过鳞状转换潜力(STP)指数进行量化。约20-30%的iCCA患者被归类为STP高表达组,并经历类似ASC的不良预后。在机制上,FOSL1作为可塑性触发因子,通过重塑染色质景观驱动时间有序的鳞状程序。此外,它以内含子依赖的方式与p63协同作用,导致PTGS2/COX-2表达失调。由此产生的肿瘤内PGE2积累驱动中性粒细胞介导的FOXP3阴性1型调节性T细胞(Tr1)极化,并使STP高表达肿瘤易对免疫治疗产生耐药性。通过药物重定位筛选,我们鉴定出塞来昔布作为一种双重功能药物,既能对抗潜在鳞状可塑性,又能促进免疫许可状态,为鳞状偏倚的iCCA提供了一种临床可行的策略,目前该策略正在一项Ib/II期临床试验(NCT07632235)中进行评估。
3肝转移切除 (1篇)
临床研究 (1篇)
To evaluate whether integrated primary tumor biology, combining primary tumor location and RAS/BRAF status, defines recurrence phenotypes and survival trajectories after liver resection for colorectal liver metastases (CRLM). Selection for resection remains largely morphology-based, although tumor biology strongly influences post-hepatectomy outcomes. Primary tumor site and RAS/BRAF status are individually prognostic, but whether their integration identifies distinct post-resection trajectories is unclear. An international multicenter cohort of patients undergoing liver resection for CRLM between 2017 and 2023 was analyzed. Integrated biology was defined a priori as left-sided-wild-type, right-sided-wild-type, rectal-wild-type, left-sided-RAS-mutant, right-sided-RAS-mutant, rectal RAS-mutant, and BRAF-mutant disease. Primary outcomes were recurrence-free survival (RFS) and overall survival (OS). Secondary outcomes included early recurrence, disseminated first recurrence, and first recurrence phenotype. Among 3162 patients from 44 centers, 2415 (76.4%) developed recurrence and 1342 (42.4%) died. Integrated biology was independently associated with both RFS and OS (global P<0.001 for both). Compared with left-WT tumors, the highest mortality risks were observed in BRAF-mutant disease [hazard ratio (HR): 2.68, 95% CI: 2.02-3.57, P<0.001] and right-RAS-mutant disease (HR: 2.32, 95% CI: 1.94-2.79, P<0.001). Integrated biology was also associated with early recurrence, disseminated first recurrence, and first recurrence phenotype. Rectal-RAS-mutant tumors had the strongest association with lung-only recurrence [relative risk ratio (RRR): 3.38, 95% CI: 2.22-5.13, P<0.001] and disseminated recurrence (RRR: 2.57, 95% CI: 1.86-3.55, P<0.001) relative to liver-only recurrence. Integrated primary tumor biology identifies clinically distinct post-hepatectomy disease trajectories after CRLM resection. Combining primary tumor site with RAS/BRAF status may support preoperative counseling, surveillance planning, and trial stratification.
中文摘要:本研究旨在评估整合的原发肿瘤生物学特征(结合原发肿瘤部位与RAS/BRAF状态)是否能在结直肠癌肝转移(CRLM)肝切除术后定义复发表型及生存轨迹。尽管目前手术选择主要基于形态学,但肿瘤生物学对肝切除后的结局具有强烈影响。虽然原发肿瘤部位和RAS/BRAF状态各自具有预后价值,但其整合是否能识别出不同的术后轨迹尚不明确。本研究分析了2017年至2023年间接受CRLM肝切除术的国际多中心患者队列数据。预先定义的整合生物学分类包括左侧野生型、右侧野生型、直肠野生型、左侧RAS突变型、右侧RAS突变型、直肠RAS突变型及BRAF突变型疾病。主要结局指标为无复发生存期(RFS)和总生存期(OS)。次要结局指标包括早期复发、首次复发的弥漫性特征以及首次复发表型。在来自44个中心的3162名患者中,2415人(76.4%)出现复发,1342人(42.4%)死亡。整合生物学特征与RFS和OS均独立相关(两者全局P值均小于0.001)。与左侧野生型肿瘤相比,BRAF突变型疾病[风险比(HR):2.68,95%置信区间(CI):2.02-3.57,P<0.001]和右侧RAS突变型疾病(HR:2.32,95% CI:1.94-2.79,P<0.001)表现出最高的死亡风险。整合生物学特征还与早期复发、首次复发的弥漫性特征及首次复发表型相关。与仅肝内复发相比,直肠RAS突变型肿瘤与仅肺转移复发[相对风险比(RRR):3.38,95% CI:2.22-5.13,P<0.001]和弥漫性复发(RRR:2.57,95% CI:1.86-3.55,P<0.001)具有最强的相关性。整合的原发肿瘤生物学特征能够识别CRLM切除术后临床上不同的肝切除后疾病轨迹。将原发肿瘤部位与RAS/BRAF状态相结合,可能有助于术前咨询、监测计划制定及试验分层。
4胆石症/胆囊 (1篇)
基础研究 (1篇)
Transforming growth factor β (TGF-β) accumulation in the tumor microenvironment (TME) is a major barrier to durable antitumor immunity. We developed fibronectin extra domain B (FN-EDB)-binding peptide (FEBP)-soluble TβRII-Fc (sTβRII), an engineered inhibitor targeting the FN-EDB-rich tumor matrix for localized TGF-β blockade. In fibrotic, immune-excluded tumors, FEBP-sTβRII suppresses TGF-β/SMAD signaling to unleash T cell activation and IFN-γ production, thereby driving feedforward cancer-associated fibroblast (CAF)-myeloid reprogramming toward an antigen-presenting state. This coordinated remodeling relieves immune exclusion and converts the fibrotic TME into an antigen-visible ecosystem that sustains robust T cell infiltration and activation. Consequently, FEBP-sTβRII induces T cell-dependent tumor regression, expands effector-memory populations, and elicits long-term, cross-protective antitumor immunity, while minimizing peripheral transcriptional disturbances compared with systemic sTβRII. Together, these findings show that spatially targeted TGF-β blockade overcomes fibrotic immune exclusion to establish durable local and systemic tumor immunity.
中文摘要:肿瘤微环境中转化生长因子β(TGF-β)的积累是持久抗肿瘤免疫的主要障碍。我们开发了纤维连接蛋白额外结构域B(FN-EDB)结合肽(FEBP)与可溶性TβRII-Fc(sTβRII)的结合体,这是一种针对富含FN-EDB的肿瘤基质以实现局部TGF-β阻断的工程化抑制剂。在纤维化且免疫排斥的肿瘤中,FEBP-sTβRII通过抑制TGF-β/SMAD信号通路释放T细胞激活并促进干扰素γ(IFN-γ)的产生,从而驱动癌症相关成纤维细胞(CAF)与髓系细胞向抗原呈递状态发生反馈性重编程。这种协同重塑缓解了免疫排斥,将纤维化的肿瘤微环境转化为维持强大T细胞浸润和激活的抗原可见生态系统。因此,FEBP-sTβRII诱导T细胞依赖性的肿瘤消退,扩大效应记忆细胞群并引发长期交叉保护的抗肿瘤免疫,同时与全身性sTβRII相比最小化了外周转录干扰。综上所述,这些发现表明空间靶向的TGF-β阻断克服了纤维化免疫排斥,建立了持久的局部和系统性肿瘤免疫。
5胰腺癌/胰十二指肠切除 (1篇)
临床研究 (1篇)
To assess the prognostic utility of the Metro-Pancreas framework in resectable pancreatic ductal adenocarcinoma (PDAC) treated with neoadjuvant chemotherapy (NAT) and resection. Upfront surgery and NAT are options in anatomically resectable PDAC. Metro-Pancreas combines tumor size and CA 19-9 to stratify prognosis after upfront resection, but its applicability after NAT is unknown. We analyzed 623 patients with nonmetastatic, anatomically resectable PDAC who underwent NAT followed by resection from 5 institutions (2016-2024). Metro-Pancreas classification (IN/OUT) was determined by tumor size and CA19-9 levels. Treatment response followed NCCN 2026 definition based on radiologic and biochemical changes. Postoperative disease-free survival (DFS) and overall survival (OS) were evaluated. At diagnosis, 263 patients (42.2%) were Metro-Pancreas OUT and had shorter postoperative DFS (13.3 vs. 16.7 mo; P=0.003) and OS (29.5 vs. 34.8 mo; P=0.006) than Metro-Pancreas IN patients. After NAT, 71.9% of OUT patients were reclassified as IN, while 5.0% of initially IN patients became OUT. Among baseline OUT patients, 35.7% had significant response, 46.0% had minimal response, and 18.3% had progression. Prognostic separation was greater at Metro-Pancreas restaging (DFS: 7.7 vs. 17.3 mo; OS: 15.8 vs. 36.7 mo; both P=0.001). Patients reclassified from OUT to IN had postoperative DFS and OS comparable to those initially IN (P=0.806 and P=0.631, respectively). Among patients undergoing resection after NAT, Metro-Pancreas stratified prognosis at diagnosis and more effectively at restaging. Reclassification from OUT to IN was associated with favorable postoperative survival, supporting dynamic prognostic reassessment in the neoadjuvant setting.
中文摘要:评估Metro-Pancreas框架在新辅助化疗联合手术治疗的解剖学可切除胰腺导管腺癌中的预后价值。对于解剖学可切除的胰腺导管腺癌,初始手术与新辅助化疗均为可选方案。Metro-Pancreas通过结合肿瘤大小和CA19-9水平来分层初始切除后的预后,但其在接受新辅助化疗后的适用性尚不明确。我们分析了2016年至2024年间来自5个机构的623例接受新辅助化疗后行切除术的非转移性、解剖学可切除胰腺导管腺癌患者数据。根据肿瘤大小和CA19-9水平确定Metro-Pancreas分类(IN或OUT)。治疗反应依据NCCN 2026定义,基于影像学和生化指标的变化进行判定。评估术后无病生存期和总生存期。诊断时,263例患者(42.2%)属于Metro-Pancreas OUT组,其术后无病生存期短于IN组患者(13.3个月对比16.7个月;P=0.003),总生存期也较短(29.5个月对比34.8个月;P=0.006)。接受新辅助化疗后,71.9%的OUT患者被重新归类为IN,而最初为IN的患者中有5.0%变为OUT。在基线OUT患者中,35.7%有显著反应,46.0%有轻微反应,18.3%出现疾病进展。在Metro-Pancreas再分期时预后分层更为明显(无病生存期:7.7个月对比17.3个月;总生存期:15.8个月对比36.7个月;均P=0.001)。从OUT重新分类为IN的患者,其术后无病生存期和总生存期与初始即为IN的患者相当(P值分别为0.806和0.631)。在接受新辅助化疗后切除的患者中,Metro-Pancreas在诊断时及再分期时均能分层预后,且在再分期时更为有效。从OUT重新分类为IN与良好的术后生存相关,支持在新辅助治疗背景下进行动态预后评估。
6胆管癌/胆道手术 (1篇)
基础研究 (1篇)
Cholangiocarcinoma (CCA) is characterized by a dense desmoplastic microenvironment dominated by cancer-associated fibroblasts (CAFs), which profoundly shape tumor behavior and diminish therapeutic efficacy. By integrating analyses of patient specimens with multi-omics profiling, mechanistic assays, tumor-CAF co-culture and xenograft models, and single-cell transcriptomics, we identified retinoic acid receptor γ (RARγ) as a central regulator of reciprocal communication between malignant cells and CAFs that promotes ferroptosis resistance. RARγ was markedly elevated in CAF-enriched tumors and associated with poor overall survival. Multi-omics integration revealed that RARγ increases CREB stability and reduces K33- and K48-linked polyubiquitination, thereby enhancing CREB occupancy at the AKR1C1 promoter and driving transcriptional activation. AKR1C1 subsequently reinforces the Nrf2-GPX4 antioxidant axis, elevates glutathione metabolism, and suppresses lipid peroxidation. Beyond intrinsic protection, RARγ induces LCN2 transcription and promotes exosomal packaging of LCN2, which is transferred to adjacent CAFs and triggers robust CSF3 (G-CSF) secretion. CAF-derived G-CSF feeds back to malignant cells to amplify RARγ expression and ferroptotic tolerance, forming a self-sustaining paracrine circuit. Single-cell RNA sequencing further supported coordinated interactions between RARG+ tumor subsets and CSF3+ CAFs, reinforcing the relevance of this signaling loop in human CCA. Collectively, these findings position RARγ as a master organizer of tumor-stroma crosstalk through the CREB-AKR1C1 and LCN2-CSF3 axes, establishing a ferroptosis-resistant niche and promoting CCA aggressiveness.
中文摘要:胆管癌(CCA)的特征是富含癌症相关成纤维细胞(CAFs)的致密促结缔组织增生微环境,这深刻影响肿瘤行为并降低治疗效果。通过整合患者标本分析、多组学谱系分析、机制实验、肿瘤与CAF共培养及异种移植模型和单细胞转录组测序,我们鉴定出视黄酸受体γ(RARγ)是恶性细胞与CAF之间促进铁死亡抵抗的相互通讯的核心调节因子。在富含CAF的肿瘤中RARγ显著升高,且与总生存期较差相关。多组学整合分析显示,RARγ增加CREB稳定性并减少K33和K48连接的聚泛素化,从而增强CREB在AKR1C1启动子上的占据率并驱动转录激活。AKR1C1随后强化Nrf2-GPX4抗氧化轴,提升谷胱甘肽代谢并抑制脂质过氧化。除了内在保护外,RARγ诱导LCN2转录并促进LCN2的外泌体包装,LCN2被转运至邻近的CAF并触发强烈的CSF3(G-CSF)分泌。CAF来源的G-CSF反馈给恶性细胞以放大RARγ表达和铁死亡耐受性,形成自我维持的旁分泌回路。单细胞RNA测序进一步支持了RARG+肿瘤亚群与CSF3+ CAF之间的协调相互作用,强化了该信号环路在人类CCA中的相关性。综上所述,这些发现将RARγ定位为通过CREB-AKR1C1和LCN2-CSF3轴组织肿瘤-间质串扰的主要组织者,建立铁死亡抵抗微环境并促进CCA的侵袭性。